Cargando…
The GluN2B-Selective Antagonist Ro 25-6981 Is Effective against PTZ-Induced Seizures and Safe for Further Development in Infantile Rats
The GluN2B subunit of NMDA receptors represents a perspective therapeutic target in various CNS pathologies, including epilepsy. Because of its predominant expression in the immature brain, selective GluN2B antagonists are expected to be more effective early in postnatal development. The aim of this...
Autores principales: | Mareš, Pavel, Kozlová, Lucie, Mikulecká, Anna, Kubová, Hana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469742/ https://www.ncbi.nlm.nih.gov/pubmed/34575558 http://dx.doi.org/10.3390/pharmaceutics13091482 |
Ejemplares similares
-
Anticonvulsant Action of GluN2A-Preferring Antagonist PEAQX in Developing Rats
por: Mares, Pavel, et al.
Publicado: (2021) -
Anticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats
por: Uttl, Libor, et al.
Publicado: (2021) -
NMDA receptor antagonists ketamine and Ro25-6981 inhibit evoked release of glutamate in vivo in the subiculum
por: Stan, T L, et al.
Publicado: (2014) -
Allosteric modulation of GluN1/GluN3 NMDA receptors by GluN1-selective competitive antagonists
por: Rouzbeh, Nirvan, et al.
Publicado: (2023) -
Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction
por: Pochwat, Bartłomiej, et al.
Publicado: (2020)